Engineering attenuated virus vaccines by controlling replication fidelity

Nature Medicine

Volumn 14, Issue 2, 2008, Pages 154-161

  Vignuzzi, Marco ^a   Wendt, Emily ^a   Andino, Raul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; RIBAVIRIN; VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC ENGINEERING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PATHOGENICITY; PHENOTYPE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION; WILD TYPE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BASE SEQUENCE; DNA-DIRECTED RNA POLYMERASES; GENETIC ENGINEERING; GENOTYPE; HELA CELLS; HUMANS; IMMUNITY; MICE; MOLECULAR SEQUENCE DATA; MUTATION; ORGAN SPECIFICITY; POLIOVIRUS; RNA, VIRAL; TROPISM; VACCINES, ATTENUATED; VARIATION (GENETICS); VIRAL VACCINES; VIRULENCE; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALIA; POLIOVIRUS;

EID: 38949184924     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1726     Document Type: Article

References (49)

1. Ada, G.L. in Fundamental Immunology (ed. Paul, W.E.) 985-1032 (Raven Press, New York, 1989).
2. Sutter, R.W., Cochi, S.L. & Melnick, J.L. Live-attenuated Poliovirus Vaccine 364-408 (W.B. Saunders, Philadelphia, 1999).
3. Zinkernagel, R.M. On natural and artificial vaccinations. Annu. Rev. Immunol. 21, 515-546 (2003).
4. Drake, J.W. The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes. Ann. NY Acad. Sci. 870, 100-107 (1999).
5. Vignuzzi, M., Stone, J.K., Arnold, J.J., Cameron, C.E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348 (2006).
6. Arnold, J.J., Vignuzzi, M., Stone, J.K., Andino, R. & Cameron, C.E. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280, 25706-25716 (2005).
7. Pfeiffer, J.K. & Kirkegaard, K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. USA 100, 7289-7294 (2003).
8. Thompson, A.A. & Peersen, O.B. Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J. 23, 3462-3471 (2004).
9. Vignuzzi, M., Stone, J.K. & Andino, R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107, 173-181 (2005).
10. Cann, A.J. et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 12, 7787-7792 (1984).
11. Minor, P.D. Polio eradication, cessation of vaccination and re-emergence of disease. Nat. Rev. Microbiol. 2, 473-482 (2004).
12. Minor, P.D., John, A., Ferguson, M. & Icenogle, J.P. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J. Gen. Virol. 67, 693-706 (1986).
13. Contreras, G. et al. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 20, 15-26 (1992).
14. Minor, P.D., Dunn, G., Ramsay, M.E. & Brown, D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J. Med. Virol. 75, 153-160 (2005).
15. Gitlin, L., Stone, J.K. & Andino, R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J. Virol. 79, 1027-1035 (2005).
16. Crotty, S., Hix, L., Sigal, L.J. & Andino, R. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J. Gen. Virol. 83, 1707-1720 (2002).
17. Racaniello, V.R. One hundred years of poliovirus pathogenesis. Virology 344, 9-16 (2006).
18. Pfeiffer, J.K. & Kirkegaard, K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 1, e11 (2005).
19. Gromeier, M. & Wimmer, E. Mechanism of injury-provoked poliomyelitis. J. Virol. 72, 5056-5060 (1998).
20. Ohka, S., Yang, W.X., Terada, E., Iwasaki, K. & Nomoto, A. Retrograde transport of intact poliovirus through the axon via the fast transport system. Virology 250, 67-75 (1998).
21. Grard, G. et al. Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology 361, 80-92 (2007).
22. Holmes, E.C. The evolution of viral emergence. Proc. Natl. Acad. Sci. USA 103, 4803-4804 (2006).
23. Holmes, E.C. Adaptation and immunity. PLoS Biol. 2, e307 (2004).
24. Aaskov, J., Buzacott, K., Thu, H.M., Lowry, K. & Holmes, E.C. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 311, 236-238 (2006).
25. Domingo, E. Viruses at the edge of adaptation. Virology 270, 251-253 (2000).
26. Domingo, E. et al. Basic concepts in RNA virus evolution. FASEB J. 10, 859-864 (1996).
27. Schuffenecker, I. et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3, e263 (2006).
28. Ciota, A.T. et al. Role of the mutant spectrum in adaptation and replication of West Nile virus. J. Gen. Virol. 88, 865-874 (2007).
29. Fernandez, G., Clotet, B. & Martinez, M.A. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J. Virol. 81, 2485-2496 (2007).
30. Sauder, C.J. et al. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 350, 48-57 (2006).
31. Vabret, A. et al. Inter- and intra-variant genetic heterogeneity of human coronavirus OC43 strains in France. J. Gen. Virol. 87, 3349-3353 (2006).
32. Tebbens, R.J. et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 26, 1471-1505 (2006).
33. Domingo, E. & Holland, J.J. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51, 151-178 (1997).
34. Holmes, E.C. & Drummond, A.J. The evolutionary genetics of viral emergence. Curr. Top. Microbiol. Immunol. 315, 51-66 (2007).
35. Palmenberg, A.C. & Sgro, J.-Y. Alignments and comparative profiles of Picornavirus Genera. in Molecular Biology of Picornaviruses (eds. Semler, B. & Wimmer, E.) 149-155 (ASM Press, Washington, DC, 2002).
36. Rotbart, H.A. Treatment of picornavirus infections. Antiviral Res. 53, 83-98 (2002).
37. Sierra, M. et al. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81, 2012-2024 (2007).
38. Anderson, J.P., Daifuku, R. & Loeb, L.A. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 58, 183-205 (2004).
39. Agol, V.I., Chumakov, K., Ehrenfeld, E. & Wimmer, E. Don't drop current vaccine until we have new ones. Nature 435, 881 (2005).
40. WHO. Global polio eradication initiative: Progress 2006. 1-32 (WHO, Geneva, 2006).
41. Dowdle, W.R., De Gourville, E., Kew, O.M., Pallansch, M.A. & Wood, D.J. Polio eradication: the OPV paradox. Rev. Med. Virol. 13, 277-291 (2003).
42. Racaniello, V.R. It is too early to stop polio vaccination. Bull. World Health Organ. 78, 359-360 (2000).
43. CDC. Prolonged poliovirus excretion in an immunodeficient person with vaccineassociated paralytic poliomyelitis. MMWR Morb. Mortal. Wkly. Rep. 46, 641-643 (1997).
44. Ogra, P.L., Leibovitz, E.E. & Zhao-Ri, G. Oral immunization and secretory immunity to viruses. Curr. Top. Microbiol. Immunol. 146, 73-81 (1989).
45. Mueller, S., Papamichail, D., Coleman, J.R., Skiena, S. & Wimmer, E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80, 9687-9696 (2006).
46. Burns, C.C. et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 80, 3259-3272 (2006).
47. Macadam, A.J. et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80, 8653-8663 (2006).
48. Gromeier, M., Alexander, L. & Wimmer, E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl. Acad. Sci. USA 93, 2370-2375 (1996).
49. Herold, J. & Andino, R. Poliovirus RNA replication requires genome circularization through a protein-protein bridge. Mol. Cell 7, 581-591 (2001).